MPT Stock Analysis: Medical Properties Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 2.437m USD | 12M Return: -1.8% | US58463J3041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.3M
Qual. Beats: 0
Rev. Trend: 7.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medical Properties Trust, Inc. (NYSE: MPT) is a self-advised real estate investment trust (REIT) focused on acquiring and developing net-leased hospital facilities. The company, which was incorporated in 2003 and went public in 2005, is headquartered in Birmingham, Alabama and operates as one of the worlds largest owners of hospital real estate, with 388 facilities and approximately 39,000 licensed beds across nine countries and three continents as of September 30, 2025.
MPTs financing model is designed to help hospital operators unlock the value of their real estate assets, enabling them to fund facility improvements, technology upgrades, and other operational investments. Under its net-lease structure, tenants are typically responsible for property-level expenses such as taxes, insurance, and maintenance, which is a common arrangement within the healthcare REIT sub-industry. REITs like MPT are generally required to distribute a substantial portion of their taxable income to shareholders in the form of dividends, a structural feature that can make them sensitive to interest rate movements.
Classified within the GICS Real Estate sector and the Health Care REITs sub-industry, MPT is positioned as a mid-cap stock with a market capitalization of approximately $2.6 billion USD. The company differentiates itself from broader diversified REITs by concentrating exclusively on hospital and acute care properties, a niche segment that ties its performance closely to the financial health of hospital operators and the broader healthcare delivery system.
- Steward Health Care defaults drive tenant credit losses
- Dividend cut undermines REIT income investor appeal
- UK NHS funding pressures threaten European hospital rents
- Asset sale program accelerates to reduce leverage ratio
| Net Income: -30.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.30 > 1.0 |
| NWC/Revenue: -87.63% < 20% (prev 47.73%; Δ -135.4% < -1%) |
| CFO/TA 0.02 > 3% & CFO 226.8m > Net Income -30.2m |
| Net Debt (9.41b) to EBITDA (1.05b): 8.95 < 3 |
| Current Ratio: 0.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (598.0m) vs 12m ago -0.46% < -2% |
| Gross Margin: 82.48% > 18% (prev 96.47%; Δ -13.99% > 0.5%) |
| Asset Turnover: 6.82% > 50% (prev 6.11%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBIT TTM 769.4m / Interest Expense TTM 646.6m) |
| A: -0.06 (Total Current Assets 396.6m - Total Current Liabilities 1.29b) / Total Assets 14.7b |
| B: -0.29 (Retained Earnings -4.21b / Total Assets 14.7b) |
| C: 0.05 (EBIT TTM 769.4m / Avg Total Assets 14.9b) |
| D: 0.44 (Book Value of Equity 4.50b / Total Liabilities 10.2b) |
| Altman-Z'' = -0.52 = B |
| DSRI: 0.86 (Receivables 945.9m/1.00b, Revenue 1.02b/925.3m) |
| GMI: 1.17 (GM 96.47% / 82.48%) |
| AQI: 1.61 (AQ_t 0.23 / AQ_t-1 0.15) |
| SGI: 1.10 (Revenue 1.02b / 925.3m) |
| TATA: -0.02 (NI -30.2m - CFO 226.8m) / TA 14.7b) |
| Beneish M = -2.56 (Cap -4..+1) = A |
As of September 02, 2026, the stock is trading at USD 4.03 with a total of 10,752,090 shares traded. Over the past week, the price has changed by -1.95%, over one month by -12.20%, over three months by -17.68% and over the past year by -1.84%.
Current recommended Stop Loss: 3.80 (which is 5.7% or 1.8 ATR below the current price).
Medical Properties Trust has no consensus analysts rating.
P/E Forward = 6.6667
P/S = 2.2052
P/B = 0.5456
P/EG = 1.6083
Revenue TTM = 1.02b USD
EBIT TTM = 769.4m USD
EBITDA TTM = 1.05b USD
Long Term Debt = 9.70b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.29b USD (from shortTermDebt, last quarter)
Debt = 9.81b USD (from shortLongTermDebtTotal, last quarter) + Leases 102.5m
Net Debt = 9.41b USD (calculated: Debt 9.81b - CCE 396.6m)
Enterprise Value = 11.8b USD (2.44b + Debt 9.81b - CCE 396.6m)
Interest Coverage Ratio = 1.19 (Ebit TTM 769.4m / Interest Expense TTM 646.6m)
EV/FCF = 52.23x (Enterprise Value 11.8b / FCF TTM 226.8m)
FCF Yield = 1.91% (FCF TTM 226.8m / Enterprise Value 11.8b)
FCF Margin = 22.25% (FCF TTM 226.8m / Revenue TTM 1.02b)
Net Margin = -2.96% (Net Income TTM -30.2m / Revenue TTM 1.02b)
Gross Margin = 82.48% ((Revenue TTM 1.02b - Cost of Revenue TTM 178.6m) / Revenue TTM)
Gross Margin QoQ = 42.11% (prev none%)
Tobins Q-Ratio = 0.80 (Enterprise Value 11.8b / Total Assets 14.7b)
Interest Expense / Debt = 6.59% (Interest Expense 646.6m / Debt 9.81b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 607.8m (EBIT 769.4m * (1 - 21.00%))
Current Ratio = 0.31 (Total Current Assets 396.6m / Total Current Liabilities 1.29b)
Debt / Equity = 2.18 (Debt 9.81b / totalStockholderEquity, last quarter 4.50b)
Debt / EBITDA = 8.95 (Net Debt 9.41b / EBITDA 1.05b)
Debt / FCF = 41.49 (Net Debt 9.41b / FCF TTM 226.8m)
Total Stockholder Equity = 4.58b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.20% (Net Income -30.2m / Total Assets 14.7b)
RoE = -0.66% (Net Income TTM -30.2m / Total Stockholder Equity 4.58b)
RoCE = 5.39% (EBIT 769.4m / Capital Employed (Equity 4.58b + L.T.Debt 9.70b))
RoIC = 4.14% (NOPAT 607.8m / Invested Capital 14.7b)
WACC = 5.62% (E(2.44b)/V(12.2b) * Re(7.26%) + D(9.81b)/V(12.2b) * Rd(6.59%) * (1-Tc(0.21)))
Discount Rate = 7.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -50.72 | Cagr: -0.17%
[DCF] Terminal Value 77.97% ; FCFF base≈211.3m ; Y1≈242.2m ; Y5≈356.5m
[DCF] Fair Price = N/A (negative equity: EV 5.36b - Net Debt 9.41b = -4.05b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 7.36 | Revenue CAGR: 1.60% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.01 | Chg30d=N/A | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=+37.50% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=0.11 | Chg30d=-25.02% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: -40% (up=0, down=2)